Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
September 03, 2024 07:08 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the closing of a new credit facility agreement with Oak Hill Advisors for a term loan of...
Goliath Intercepts The Highest Concentration Of Visible Gold To Date At Surebet Where 66% Of 2024 Drill Holes Contain Visible Gold, Discovers New Deep Mineralized Zone 1.2 Km Below Surface, Remains Open, And Significantly Expands Drilling To 36,000 Meters With 8 Rigs Turning
September 03, 2024 07:08 ET
|
Goliath Resources Limited
Surebet Drill Highlights: Drill hole GD-24-260 has the highest concentration of Visible Gold drilled to date at the Surebet Discovery. This intercept suggests this structure is a principal conduit...
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024 07:07 ET
|
Vaxcyte, Inc.
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity...
Video Conferencing Solutions Market to Reach $49.7 Billion, Globally, by 2032 at 13.7% CAGR: Allied Market Research
September 03, 2024 07:07 ET
|
Allied Analytics LLP
NEW CASTLE, Delaware, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Video Conferencing Solutions Market by Deployment Mode (On-premise and Cloud), by...
DXCM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
September 03, 2024 07:05 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024...
Next-Gen Communication Protocols Market to Reach $259.3 Billion, Globally, by 2032 at 20.9% CAGR: Allied Market Research
September 03, 2024 07:05 ET
|
Allied Analytics LLP
NEW CASTLE, Delaware, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Next-Gen Communication Protocols Market by Technology (Wireless Communication...
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 03, 2024 07:05 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024 07:05 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
September 03, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
September 03, 2024 07:01 ET
|
Invivyd
New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants testedCenter for Disease Control...